Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lowered by Oppenheimer from $53.00 to $52.00 in a research report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. increased their price […]
Operator: Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will be in the listen-only mode.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 EPS estimates for Kymera Therapeutics in a research note issued to investors on Friday, February 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.79) for the quarter. The consensus […]